Liver fibrosis protects mice from acute hepatocellular injury

Gastroenterology. 2012 Jan;142(1):130-139.e4. doi: 10.1053/j.gastro.2011.09.033. Epub 2011 Sep 21.

Abstract

Background & aims: Development of fibrosis is part of the pathophysiologic process of chronic liver disease. Although it is considered deleterious, it also represents a form of tissue repair. Deposition of extracellular matrix changes the cellular environment of the liver; we investigated whether it increases resistance to noxious stimuli and the role of changes in intracellular signaling to hepatocytes in mediating this effect.

Methods: Primary cultures of mouse hepatocytes were exposed to type I collagen (COL1); cell injury was assessed by morphologic and biochemical criteria. The expression of Bcl-2 family members was evaluated by immunoblot analyses. Activation of extracellular signal-regulated kinase (ERK) was assessed using phospho-specific antibodies. Liver fibrosis was induced by repeated administration of thioacetamide or carbon tetrachloride to mice; mice were then exposed to Fas antibodies.

Results: Hepatocytes exposed to COL1 were more resistant to a variety of hepatotoxins, in a dose-dependent manner, and had lower levels of Bad, Bid, and Bax proapoptotic proteins compared with control hepatocytes. Activation of ERK1/2 was stronger and quicker in hepatocytes exposed to COL1. The MEK1/2 inhibitors U0126 and PD98059 reversed the protective effects of COL1 and the decrease in proapoptotic proteins. Hepatocytes isolated from ERK1(-/-) mice were insensitive to the protective effect of COL1. Fibrotic livers from wild-type mice had high levels of phospho-ERK1 and were resistant to Fas-induced cell death. ERK1(-/-) mice lost this effect.

Conclusions: Production of COL1 during liver fibrosis induces a hepatoprotective response that is mediated by activation of ERK1 signaling.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Animals
  • Apoptosis
  • BH3 Interacting Domain Death Agonist Protein / metabolism
  • Blotting, Western
  • Carbon Tetrachloride
  • Cells, Cultured
  • Chemical and Drug Induced Liver Injury / etiology
  • Chemical and Drug Induced Liver Injury / metabolism
  • Chemical and Drug Induced Liver Injury / pathology
  • Chemical and Drug Induced Liver Injury / prevention & control*
  • Collagen Type I / metabolism
  • Cytoprotection
  • Enzyme Activation
  • Liver / drug effects
  • Liver / metabolism
  • Liver / pathology*
  • Liver Cirrhosis, Experimental / chemically induced
  • Liver Cirrhosis, Experimental / metabolism
  • Liver Cirrhosis, Experimental / pathology*
  • MAP Kinase Kinase 1 / antagonists & inhibitors
  • MAP Kinase Kinase 1 / metabolism
  • MAP Kinase Kinase 2 / antagonists & inhibitors
  • MAP Kinase Kinase 2 / metabolism
  • Mice
  • Mice, Inbred BALB C
  • Mice, Knockout
  • Mitogen-Activated Protein Kinase 1 / genetics
  • Mitogen-Activated Protein Kinase 1 / metabolism
  • Mitogen-Activated Protein Kinase 3 / genetics
  • Mitogen-Activated Protein Kinase 3 / metabolism
  • Phosphorylation
  • Protein Kinase Inhibitors / pharmacology
  • Signal Transduction
  • Thioacetamide
  • Time Factors
  • bcl-2-Associated X Protein / metabolism
  • bcl-Associated Death Protein / metabolism
  • fas Receptor / metabolism

Substances

  • BH3 Interacting Domain Death Agonist Protein
  • Bad protein, mouse
  • Bax protein, mouse
  • Bid protein, mouse
  • Collagen Type I
  • Protein Kinase Inhibitors
  • bcl-2-Associated X Protein
  • bcl-Associated Death Protein
  • fas Receptor
  • Thioacetamide
  • Carbon Tetrachloride
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3
  • MAP Kinase Kinase 1
  • MAP Kinase Kinase 2
  • Map2k1 protein, mouse
  • Map2k2 protein, mouse